PrenatalSAFE Karyo

is the most technologically advanced genome-wide non-invasive prenatal test (NIPT) currently available.Through cell free fetal DNA (cfDNA) analysis from maternal plasma, PrenatalSAFE® Karyo detects: aneuploidies and structural chromosomal aberrations (deletions or duplications) across the fetal genome, providing karyotype-level insight.

 Brochure PrenatalSAFE Karyo
PrenatalSAFE Karyo

PrenatalSAFE® Karyo test couples leading technology with unparalleled insights to offer the most advanced information available from a non-invasive test. PrenatalSAFE® Karyo is a cell-free fetal DNA (cfDNA)-based noninvasive prenatal test that analyzes every chromosome in the fetal genome.

Like most NIPTs, it can screen for common chromosomal abnormalities, such as Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome) and sex chromosome aneuploidies (Monosomy X, Trisomy X, XXY and XYY). But it can also find other chromosomal changes that may go undiagnosed at birth, such as structural chromosomal aberrations (deletions or duplications), rare aneuploidies (e.g. Trisomy 9, 16, 22), across the entire fetal genome, and analyzes 9 clinically significant microdeletion regions, something other NIPTs do not currently do.

PrenatalSAFE Karyo

is the next level in non-invasive prenatal testing

prenatalsafe karyo vs other nipts

Unlike any other noninvasive prenatal test (NIPT) available to date, focusing only on detection of common aneuploidies (Trisomy 21, Trisomy 18, Trisomy 13 and Sex Chromosomes aneuploidy), PrenatalSAFE®Karyo offers a level of information previously only available from a fetal karyotype analysis, performed with invasive prenatal diagnosis procedures (amniocentesis and CVS).